# HB-adMSCs vs Placebo for the Treatment of Juvenile Idiopathic Arthritis

> **NCT06623240** · PHASE2 · WITHDRAWN · sponsor: **Hope Biosciences Research Foundation**

## Conditions studied

- Juvenile Idiopathic Arthritis (JIA)

## Interventions

- **BIOLOGICAL:** allogeneic Hope Biosciences adipose-derived mesenchymal stem cells
- **OTHER:** Normal Saline Solution 0.9%

## Key facts

- **NCT ID:** NCT06623240
- **Lead sponsor:** Hope Biosciences Research Foundation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2026-01
- **Primary completion:** 2026-01
- **Final completion:** 2026-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** In the time that the site has been active, there have been 0 patients enrolled despite our best efforts. It is clear that it is not feasible to conduct this study at this time; therefore, we have withdrawn this study.
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06623240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06623240, "HB-adMSCs vs Placebo for the Treatment of Juvenile Idiopathic Arthritis". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06623240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*